Search
for
Sort by
Research 91–120 of 585
- Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia
- Alopecia Areata
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- Novel therapies for alopecia areata: The era of rational drug development
- Role of skin enzymes in metabolism of topical drugs
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Dermatologic Adverse Events from Cancer Treatments
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Clinical Trials and Hair Loss
- Alopecia Areata
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Treatment of frontal fibrosing alopecia: literature review 2020-2025
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Alopecia Areata: Current Review
- Alopecia Totalis Treated with 1064 nm Picosecond Nd:YAG Laser: A Case Report
- Alopecia Areata
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- Noval advance of histone modification in inflammatory skin diseases and related treatment methods
- Hair Loss in Children
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Poster Abstracts
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies